Literature DB >> 20345979

Mitigation of septic shock in mice and rhesus monkeys by human chorionic gonadotrophin-related oligopeptides.

N A Khan1, M P M Vierboom, C van Holten-Neelen, E Breedveld, E Zuiderwijk-Sick, A Khan, I Kondova, G Braskamp, H F J Savelkoul, W A Dik, B A 't Hart, R Benner.   

Abstract

The marked improvement of several immune-mediated inflammatory diseases during pregnancy has drawn attention to pregnancy hormones as potential therapeutics for such disorders. Low molecular weight fractions derived from the pregnancy hormone human chorionic gonadotrophin (hCG) have remarkable potent immunosuppressive effects in mouse models of diabetes and septic shock. Based on these data we have designed a set of oligopeptides related to the primary structure of hCG and tested these in models of septic shock in mice and rhesus monkeys. We demonstrate that mice exposed to lipopolysaccharide (LPS) and treated subsequently with selected tri-, tetra-, penta- and hepta-meric oligopeptides (i.e. MTR, VVC, MTRV, LQGV, AQGV, VLPALP, VLPALPQ) are protected against fatal LPS-induced septic shock. Moreover, administration of a cocktail of three selected oligopeptides (LQGV, AQGV and VLPALP) improved the pathological features markedly and nearly improved haemodynamic parameters associated with intravenous Escherichia coli-induced septic shock in rhesus monkeys. These data indicate that the designed hCG-related oligopeptides may present a potential treatment for the initial hyperdynamic phase of septic shock in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345979      PMCID: PMC2883119          DOI: 10.1111/j.1365-2249.2010.04112.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

3.  Inhibition of diabetes in NOD mice by human pregnancy factor.

Authors:  N A Khan; A Khan; H F Savelkoul; R Benner
Journal:  Hum Immunol       Date:  2001-12       Impact factor: 2.850

Review 4.  Markers of endothelial damage in organ dysfunction and sepsis.

Authors:  Konrad Reinhart; Ole Bayer; Frank Brunkhorst; Michael Meisner
Journal:  Crit Care Med       Date:  2002-05       Impact factor: 7.598

5.  Pathophysiologic importance of E- and L-selectin for neutrophil-induced liver injury during endotoxemia in mice.

Authors:  J A Lawson; A R Burns; A Farhood; M Lynn Bajt; R G Collins; C W Smith; H Jaeschke
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

6.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

7.  Inhibition of septic shock in mice by an oligopeptide from the beta-chain of human chorionic gonadotrophin hormone.

Authors:  Nisar A Khan; Afshan Khan; Huub F J Savelkoul; Robbert Benner
Journal:  Hum Immunol       Date:  2002-01       Impact factor: 2.850

8.  Preparation and analysis of the common urinary forms of human chorionic gonadotropin.

Authors:  S Birken; Y Maydelman; M A Gawinowicz
Journal:  Methods       Date:  2000-05       Impact factor: 3.608

9.  Deaths: preliminary data for 2002.

Authors:  Kenneth D Kochanek; Betty L Smith
Journal:  Natl Vital Stat Rep       Date:  2004-02-11

10.  Synthetic oligopeptides related to the [beta]-subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hemorrhagic shock and resuscitation.

Authors:  H Rogier van den Berg; Nisar A Khan; Marten van der Zee; Fred Bonthuis; Jan N M IJzermans; Willem A Dik; Ron W F de Bruin; Robbert Benner
Journal:  Shock       Date:  2009-03       Impact factor: 3.454

View more
  10 in total

Review 1.  Immunomodulatory and Kidney-Protective Effects of the Human Chorionic Gonadotropin Derivate EA-230.

Authors:  Roger van Groenendael; Matthijs Kox; Lucas T van Eijk; Peter Pickkers
Journal:  Nephron       Date:  2018-07-06       Impact factor: 2.847

2.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.

Authors:  Christian Hinderer; Nathan Katz; Elizabeth L Buza; Cecilia Dyer; Tamara Goode; Peter Bell; Laura K Richman; James M Wilson
Journal:  Hum Gene Ther       Date:  2018-02-12       Impact factor: 5.695

3.  A randomized double-blind, placebo-controlled clinical phase IIa trial on safety, immunomodulatory effects and pharmacokinetics of EA-230 during experimental human endotoxaemia.

Authors:  Roger van Groenendael; Matthijs Kox; Guus Leijte; Bouke Koeneman; Jelle Gerretsen; Lucas van Eijk; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

4.  Pharmacokinetics, safety and tolerability of the novel β-hCG derived immunomodulatory compound, EA-230.

Authors:  Roger van Groenendael; Rob Aarnoutse; Matthijs Kox; Lucas van Eijk; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2019-06-02       Impact factor: 4.335

5.  The Safety, Tolerability, and Effects on the Systemic Inflammatory Response and Renal Function of the Human Chorionic Gonadotropin Hormone-Derivative EA-230 Following On-Pump Cardiac Surgery (The EASI Study): Protocol for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.

Authors:  Roger van Groenendael; Remi Beunders; Jan Hofland; Wim J Morshuis; Matthijs Kox; Lucas T van Eijk; Peter Pickkers
Journal:  JMIR Res Protoc       Date:  2019-02-06

6.  Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study.

Authors:  Roger van Groenendael; Remi Beunders; Pleun Hemelaar; Jan Hofland; Wim J Morshuis; Johannes G van der Hoeven; Jelle Gerretsen; Gert Wensvoort; Emma J Kooistra; Wout J Claassen; Denise Waanders; Maud G A Lamberts; Leonie S E Buijsse; Matthijs Kox; Lucas T van Eijk; Peter Pickkers
Journal:  Crit Care Med       Date:  2021-05-01       Impact factor: 9.296

7.  Recombinant Fasciola hepatica Fatty Acid Binding Protein as a Novel Anti-Inflammatory Biotherapeutic Drug in an Acute Gram-Negative Nonhuman Primate Sepsis Model.

Authors:  Jose J Rosado-Franco; Albersy Armina-Rodriguez; Nicole Marzan-Rivera; Armando G Burgos; Natalie Spiliopoulos; Stephanie M Dorta-Estremera; Loyda B Mendez; A M Espino
Journal:  Microbiol Spectr       Date:  2021-12-22

Review 8.  A comparative review of toll-like receptor 4 expression and functionality in different animal species.

Authors:  Céline Vaure; Yuanqing Liu
Journal:  Front Immunol       Date:  2014-07-10       Impact factor: 7.561

9.  Outlining key inflammation-associated parameters during early phase of an experimental gram-negative sepsis model in rhesus macaques (Macaca mulatta).

Authors:  Jose J Rosado-Franco; Marcos J Ramos-Benitez; Laura M Parodi; Derick Rosario; Nicole Compo; Luis D Giavedoni; Ana M Espino
Journal:  Animal Model Exp Med       Date:  2019-10-08

Review 10.  How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?

Authors:  Adriana Barreto-Santamaría; Gabriela Arévalo-Pinzón; Manuel A Patarroyo; Manuel E Patarroyo
Journal:  Antibiotics (Basel)       Date:  2021-12-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.